Ocular Therapeutix Inc Revenue Growth Rates (OCUL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ocular Therapeutix Inc   (NASDAQ: OCUL)
 

OCUL's Revenue Growth by Quarter and Year

Ocular Therapeutix Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OCUL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 13.48
1st Quarter March 10.79
FY 24.27

OCULs Annual Revenue
Ocular Therapeutix Inc 's Revenue in the fiscal year 2025 $ 51.95 millions
Ocular Therapeutix Inc 's Revenue in the fiscal year 2024 $ 63.72 millions
Ocular Therapeutix Inc 's Revenue in the fiscal year 2023 $ 58.44 millions
Ocular Therapeutix Inc 's Revenue in the fiscal year 2022 $ 51.49 millions
Ocular Therapeutix Inc 's Revenue in the fiscal year 2021 $ 43.52 millions




OCUL Revenue second quarter 2026 Y/Y Growth Comment
Ocular Therapeutix Inc reported Revenue growth of 0.11% year on year in the second quarter 2026, to $ 13.48 millions, this is lower than Ocular Therapeutix Inc 's recent average Revenue surge of 110.44%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Revenue growth. While Ocular Therapeutix Inc ' s Revenue increase of 0.11% ranks overall at the positon no. 2780 in the second quarter 2026.


OCUL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -22.42 % 15.41 % 5.11 %
3rd Quarter September - -5.77 % 2.32 % 25.98 %
2nd Quarter June 0.11 % -18.13 % 8.23 % 23.8 %
1st Quarter March 0.84 % -27.56 % 10.47 % 1.36 %
FY   - -18.47 % 9.03 % -

Financial Statements
Ocular Therapeutix Inc 's second quarter 2026 Revenue $ 13.48 millions OCUL's Income Statement
Ocular Therapeutix Inc 's second quarter 2025 Revenue $ 13.46 millions Quarterly OCUL's Income Statement


OCUL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -8.87 % 10.69 % -1.86 %
3rd Quarter September - 8.02 % -6.14 % -0.72 %
2nd Quarter June 24.88 % 25.79 % 11.31 % 13.61 %
1st Quarter March -18.57 % -37.35 % -0.2 % -5.04 %
FY (Year on Year)   - -18.47 % 9.03 % -


Back to OCUL Growth rate Comparisons >> Back to OCUL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #392
Overall #2780

Revenue Y/Y Growth Statistics
High Average Low
1477.78 % 110.44 % -28.42 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #392
Overall #2780
Revenue Y/Y Growth Statistics
High Average Low
1477.78 % 110.44 % -28.42 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ocular Therapeutix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
274.51 % 24.49 % -39.86 %
(Sep 30 2020)  


OCUL's II. Quarter Q/Q Revenue Comment
Ocular Therapeutix Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 24.88%, to $ 13.48 millions, from $10.79 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Ocular Therapeutix Inc 's Revenue growth quarter on quarter, overall rank is 428.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #94
Overall #428
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #94
Overall #428
Revenue Q/Q Growth Statistics
High Average Low
274.51 % 24.49 % -39.86 %
(Sep 30 2020)  


OCUL's II. Quarter Q/Q Revenue Comment
Ocular Therapeutix Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 24.88%, to $ 13.48 millions, from $10.79 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Ocular Therapeutix Inc 's Revenue growth quarter on quarter, overall rank is 428.


Ocular Therapeutix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 52.05 $ 52.04 $ 51.95 $ 55.78 $ 56.66
Y / Y Revenue Growth (TTM) -8.14 % -12.76 % -18.47 % -9.21 % -7.26 %
Year on Year Revenue Growth Overall Ranking # 3308 # 3990 # 3174 # 3070 # 2476
Seqeuential Revenue Change (TTM) 0.03 % 0.17 % -6.87 % -1.55 % -5 %
Seq. Revenue Growth (TTM) Overall Ranking # 3308 # 3990 # 3174 # 3070 # 2476


Cumulative Revenue growth Comment
Ocular Therapeutix Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Ocular Therapeutix Inc 's annual Revenue decline would be -8.14% year on year to $52 millions.

In the Healthcare sector 419 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3308, from total ranking in previous quarter at 3990.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 420
Overall # 3109

Revenue TTM Y/Y Growth Statistics
High Average Low
397.37 %
 63.96 %
-18.47 %
(Sep 30 2020)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 414
S&P 500 # 3010
Cumulative Revenue growth Comment
Ocular Therapeutix Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Ocular Therapeutix Inc 's annual Revenue fall would be -8.14% year on year to $52 millions.

In the Healthcare sector 419 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3308, from total ranking in previous quarter at 3990.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 420
Overall # 3109

Revenue TTM Y/Y Growth Statistics
High Average Low
397.37 %
63.96 %
-18.47 %
(Sep 30 2020)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 414
S&P 500 # 3010




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OCUL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ocular Therapeutix Inc 0.12%$ 0.119 millions


About Ocular Therapeutix Inc Revenue Growth Rates (OCUL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ocular Therapeutix Inc (CIK 1393434).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-089450
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ocular Therapeutix Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.